Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk:a nationwide study by Thein, David et al.
 
  
 
Aalborg Universitet
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate
cardiovascular risk
a nationwide study
Thein, David; Christiansen, Mia Nielsen; Mogensen, Ulrik Madvig; Bundgaard, Johan Skov;
Rørth, Rasmus; Madelaire, Christian; Fosbøl, Emil Loldrup; Schou, Morten; Torp-Pedersen,
Christian; Gislason, Gunnar; Køber, Lars; Kristensen, Søren Lund
Published in:
Cardiovascular Diabetology
DOI (link to publication from Publisher):
10.1186/s12933-020-01078-5
Creative Commons License
CC BY 4.0
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Thein, D., Christiansen, M. N., Mogensen, U. M., Bundgaard, J. S., Rørth, R., Madelaire, C., Fosbøl, E. L.,
Schou, M., Torp-Pedersen, C., Gislason, G., Køber, L., & Kristensen, S. L. (2020). Add-on therapy in metformin-
treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovascular
Diabetology, 19(1), [107]. https://doi.org/10.1186/s12933-020-01078-5
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Thein et al. Cardiovasc Diabetol          (2020) 19:107  
https://doi.org/10.1186/s12933-020-01078-5
ORIGINAL INVESTIGATION
Add-on therapy in metformin-treated 
patients with type 2 diabetes at moderate 
cardiovascular risk: a nationwide study
David Thein1, Mia Nielsen Christiansen1, Ulrik Madvig Mogensen1, Johan Skov Bundgaard1, Rasmus Rørth1, 
Christian Madelaire2, Emil Loldrup Fosbøl1, Morten Schou2, Christian Torp‑Pedersen3, Gunnar Gislason2,4,5, 
Lars Køber1 and Søren Lund Kristensen1* 
Abstract 
Background: In randomised clinical trials, glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) and sodium–glu‑
cose cotransporter 2 (SGLT‑2) inhibitors reduced cardiovascular events in patients with type 2 diabetes (T2D) at high 
cardiovascular risk, as compared to standard care. However, data comparing these agents in patients with T2D who 
are at moderate risk is sparse.
Methods: From Danish national registries, we included patients with T2D previously on metformin monotherapy, 
who started an additional glucose‑lowering agent [GLP‑1 RA, SGLT‑2 inhibitor, dipeptidyl peptidase‑4 (DPP‑4) inhibi‑
tor, sulfonylurea (SU), or insulin] in the period 2010‑2016. Patients with a history of cardiovascular events [heart failure 
(HF), myocardial infarction (MI) or stroke] were excluded. Patients were followed for up to 2 years. Cause‑specific 
adjusted Cox regression models were used to compare the risk of hospitalisation for HF, a composite endpoint of 
major adverse cardiovascular events (MACE) (MI, stroke or cardiovascular death), and all‑cause mortality for each add‑
on therapy. Patients who initiated DPP‑4 inhibitors were used as reference.
Results: The study included 46,986 T2D patients with a median age of 61 years and of which 59% were male. The 
median duration of metformin monotherapy prior to study inclusion was 5.3 years. Add‑on therapy was distributed as 
follows: 13,148 (28%) GLP‑1 RAs, 2343 (5%) SGLT‑2 inhibitors, 15,426 (33%) DPP‑4 inhibitors, 8917 (19%) SUs, and 7152 
(15%) insulin. During follow‑up, 623 (1.3%, range 0.8‑2.1%) patients were hospitalised for HF—hazard ratios (HR) were 
1.11 (95% CI 0.89–1.39) for GLP‑1 RA, 0.84 (0.52–1.36) for SGLT‑2 inhibitors, 0.98 (0.77–1.26) for SU and 1.54 (1.25–1.91) 
for insulin. The composite MACE endpoint occurred in 1196 (2.5%, range 1.5–3.6%) patients, yielding HRs of 0.82 
(0.69–0.97) for GLP‑1 RAs, 0.79 (0.56–1.12) for SGLT‑2 inhibitors, 1.22 (1.03–1.49) for SU and 1.23 (1.07–1.47) for insulin. 
1865 (3.9%, range 1.9–9.0%) died from any cause during follow‑up. HRs for all‑cause mortality were 0.91 (0.78–1.05) for 
GLP‑1 RAs, 0.79 (0.58–1.07) for SGLT‑2 inhibitors, 1.13 (0.99–1.31) for SU and 2.33 (2.08–2.61) for insulin.
Conclusion: In a nationwide cohort of metformin‑treated T2D patients and no history of cardiovascular events, the 
addition of either GLP‑1 RA or SGLT‑2 inhibitor to metformin treatment was associated with a similar risk of hospi‑
talisation for HF and death, and a lower risk of MACE for GLP‑1 RA when compared with add‑on DPP‑4 inhibitors. By 
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Background
In patients with type 2 diabetes (T2D), cardiovascular 
disease is the primary cause of death, often due to an 
increased risk of myocardial infarction (MI), stroke, 
and heart failure (HF) [1–4]. The prevalence of HF is 
> 20% in patients with T2D aged ≥ 65 years. This group 
of patients is at an increased risk of death, with an 
expected median time lifetime of 4–5  years for com-
bined HF, T2D and age ≥ 65 years [5].
In recent guidelines concerning T2D, the recommen-
dations on first- and second-line therapy have been 
updated, and take into account the cardiovascular (CV) 
risk profile of the patient [6–8]. For patients consid-
ered to have atherosclerotic CV disease or be at a high 
or very high CV risk, Glucagon-like peptide-1 receptor 
agonists (GLP-1 RA) or sodium–glucose cotransporter 
2 (SGLT-2) inhibitors are recommended over dipepti-
dyl peptidase-4 (DPP-4) inhibitors or sulfonylurea (SU) 
as add-on therapy to metformin—and in certain cases, 
GLP-1 RAs and SGLT-2 inhibitors are recommended 
as first line therapy. These recommendations are based 
on CV outcome trials that included patients with T2D 
and either an established CV disease or a high CV risk 
profile [6–8]. These trials have shown a reduction in 
atherosclerotic events with GLP-1 RAs, and for SGLT-2 
inhibitors a reduction in hospitalisation for HF, adverse 
renal outcomes and all-cause mortality [9–18]. Car-
diovascular outcome trials on dipeptidyl peptidase-4 
(DPP-4) inhibitors have not demonstrated similar car-
diovascular or renal benefits [19–23].
Importantly, meta-analyses have suggested that 
the cardiovascular benefits of GLP-1 RA and SGLT-2 
inhibitors may primarily be present in patients where 
treatment is administered as a secondary prevention 
initiative e.g. in patients with an established CV disease 
[17, 24]. Previous observational studies have shown 
SGLT-2 inhibitors to be associated with improved car-
diovascular outcomes, but in these studies the majority 
of patients had established CV disease [12, 16].
The aim of the present study is to investigate whether 
the benefits associated with use of GLP-1 RAs and 
SGLT-2 inhibitors extend to patients with T2D at a 
lower CV risk in a nationwide Danish cohort. Thus, 
we compare the incidence of cardiovascular events in 
relation to add-on glucose-lowering therapy in patients 
who initiated second-line add-on therapy to metformin 
and had no history of CV events [16, 25].
Methods
Setting
The Danish health-care system is based on the Beveridge 
model, offering free access to health services throughout 
the primary, secondary, and tertiary sector. The preva-
lence of T2D in Denmark is estimated to be 6%, which 
is comparable to that of the USA (7%) and the UK (5%) 
[26, 27]. From 2010 to 2016, the Danish and interna-
tional guidelines on the treatment of T2D recommended 
that the treating physician add any of the listed therapies 
(GLP-1 RA, SGLT-2 and DPP-4 inhibitor, SU, and insu-
lin) alongside metformin, if glycaemic control was not 
achieved with metformin monotherapy [28].
Data sources
All Danish residents are assigned a unique personal iden-
tification number at birth or upon immigration. This 
identification allows for linkage of data across differ-
ent national registries. In this study, we combined data 
from the following data sources; (1) The Danish National 
Patient Registry which holds information on all hospital 
admissions since 1978, and outpatient visits since 1995. 
Diagnoses are coded according to the International Clas-
sification of Diseases (ICD-10). The ICD-10 codes used 
for outcomes in the present study have been validated 
and have a positive predictive value of > 90% for the out-
comes of MI, stroke, and HF [29, 30]. (2) The Danish Reg-
ister of Medicinal Product Statistics (also known as the 
national prescription registry) contains information on 
all dispensed prescriptions since 1995. The international 
Anatomical Therapeutical Chemical (ATC) system is 
used to classify dispensed drugs [31]. National Pharma-
cies are required by law to register all dispensed prescrip-
tions due to the national subsidiaries on drug expenses. 
(3) The National Population Registry contains informa-
tion on sex, vital status, date of birth, and, if applicable, 
date of death.
Study population and baseline variables
The study population was composed of patients with 
T2D on metformin monotherapy who initiated add-on 
therapy between the 1st of January 2010 and the 31st of 
December 2016. Patients with T2D were defined as those 
with the presence of ICD-10 code E11 from the Danish 
National Patient Registry or a filled prescription for met-
formin. Initiation of second-line add-on therapy (GLP-1 
RA, SGLT-2 inhibitor, DPP-4 inhibitor, SU, or insulin) 
contrast, initiation of treatment with SU and insulin were associated with a higher risk of MACE. Additionally, insulin 
was associated with an increased risk of all‑cause mortality and hospitalisation for HF.
Keywords: Type 2 diabetes, Heart failure, Myocardial infarction, Prognosis, Treatment
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was defined by the following criteria; (1) a filled prescrip-
tion for one of the examined glucose-lowering therapies 
(2) no previous history of any glucose-lowering therapy 
apart from metformin, and (3) a filled prescription for 
metformin during a 6 month period prior to the begin-
ning of the add-on therapy, and again during a 3 month 
period after the initiation of add-on therapy (Fig.  1). 
These criteria were applied to ensure that the included 
patients required intensified treatment for T2D. Conse-
quently, the date of inclusion was set 3 months after the 
initiation of add-on therapy to avoid immortal time bias. 
Patients were excluded if they had a history of hospitali-
sation for HF, MI, or stroke prior to the date of inclusion.
Comorbidities were defined by the presence of rele-
vant ICD-10 codes acquired during hospitalisation over 
a 10-year period leading up to the date of inclusion. 
The comorbidities included were hypertension, atrial 
fibrillation, cancer, chronic obstructive pulmonary dis-
ease, ischemic heart disease, peripheral atherosclerosis, 
renal disease, and thyroid disease (for ICD-10 codes see 
Additional file 1: Table S1). Ongoing pharmacotherapy 
was defined by at least one filled prescription for any 
of the following drugs during the 6  months prior to 
the date of inclusion: Angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin-II blockers inhibitors, 
acetylsalicylic acid, calcium channel blockers, digoxin, 
clopidogrel, mineralocorticoid receptor antagonists, 
statins, β-blockers and loop diuretics (for ATC codes 
see Additional file  1: Table  S1). The duration of met-
formin monotherapy was estimated as the time differ-
ence between the first filled prescription for metformin 
and the initiation of the respective add-on therapy. The 
CV risk of the included patients was assessed in accord-
ance with the recently published EASD/ESC guidelines 
on management of CV risk in diabetes within the limits 
of the national patient registries [6]. Patients were clas-
sified as being at moderate risk due to their T2D sta-
tus alone. Additionally, patients were deemed to be at 
high risk if the duration of T2D exceed 10 years, and at 
very high risk if the patient had a history of peripheral 
vascular disease, ischemic heart disease, or chronic kid-
ney disease.
Stratification, exposure, and outcomes
Patients were grouped according to the initiated add-
on therapy (GLP-1 RAs, SGLT-2 inhibitors, DPP-4 
inhibitors, SU, or insulin). Patients were followed until 
an event occurred, the 1st of August 2017, or for a 
maximum follow-up of 2  years. The two-year follow-
up was chosen based on a preliminary analysis on the 
median time patients remained in the same add-on 
therapy group. For analyses, patients stayed in their 
initial assigned group irrespective of potential changes 
in treatment throughout follow-up. This approach was 
chosen to avoid unnecessary complexity in the inter-
pretation of results, as changes in glucose-lowering 
treatment during follow-up may be influenced by a 
multitude of factors including possible suspicion of car-
diovascular disease. The primary outcome of the study 
was hospitalisation for HF. The study had two second-
ary outcomes; a composite endpoint of major adverse 
cardiovascular events (MACE) in the form of MI, stroke 
or CV death, and all-cause mortality. Hospitalisation 
for HF was chosen as the primary endpoint due to the 
results presented in the CV outcome trials indicating 
beneficial effects on this outcome. Discontinuation of 
treatment or introduction of insulin was assessed in 
sensitivity analyses. The group starting DPP-4 inhibitor 
treatment was chosen as reference, as it included the 
majority of patients and underwent an initial introduc-
tion to market in the studied time period, which was 
also the case for GLP-1 RA and SGLT-2 inhibitors.
Statistics
For baseline characteristics, differences between groups 
were compared by ANOVA or Friedman test for con-
tinuous variables, and Pearson’s chi-squared test for cat-
egorical variables. P-values were reported for ANOVA 
and Friedman test. Categorical variables were compared 
Fig. 1 Graphical representation of the criteria for add‑on therapy
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with DPP-4 inhibitors (reference) by Bonferroni cor-
rected multiple comparison and statistically significant 
differences were highlighted. The primary outcome of 
hospitalisation for HF and the secondary outcomes of 
MACE and all-cause mortality were analysed by cause-
specific Cox-proportional hazard regression adjusted for 
age, sex, comorbidities (hypertension, atrial fibrillation, 
cancer, chronic obstructive pulmonary disease, ischemic 
heart disease, peripheral atherosclerosis, renal disease, 
microvascular complications, and thyroid disease), use of 
statins, CV risk profile, duration of metformin monother-
apy, and year of inclusion. DPP-4 inhibitors were used as 
reference. We tested for interaction between treatment 
effects, sex, and age respectively by a likelihood ratio test 
and found no significant interactions unless stated other-
wise. All parameters were tested to be in accordance with 
the proportional hazard assumptions. Event rates were 
calculated per 1000 person-years, accounting for the 
competing risk of death. For all analyses, a p value < 0.05 
was considered statistically significant. The following five 
sensitivity analyses were conducted: (1) Patients were fol-
lowed until a prescription was filled for any anti-diabetic 
therapy different from the initial treatment, (2) Follow-
up was extended to 3  years, (3) Patients were stratified 
according to their CV risk (4) The cohort was split in two 
based the date of inclusion (before and after September 
2013), (5) SU was used as reference. All statistical analy-
ses were conducted in the SAS statistical software pack-
age, version 9.4 (SAS Institute, Cary, NC).
Results
Baseline characteristics
A total of 55,460 patients on metformin monotherapy 
fulfilled the inclusion criteria of starting an additional 
glucose-lowering agent. Of these, 8153 patients were 
excluded due to a history of MI, stroke, or hospitalisa-
tion for HF, 213 were excluded due to the occurrence of 
death between the initiation of add-on therapy and the 
date of inclusion, and 108 were excluded due to insuf-
ficient data (Fig.  2). The remaining 46,986 patients had 
the following distribution: 13,148 (28%) in GLP-1 RAs, 
2343 (5%) in SGLT-2 inhibitors, 15,426 (33%) in DPP-4 
inhibitors, 8917 (19%) in SU, and 7152 (15%) in insulin 
(Fig. 2). The median duration of metformin monotherapy 
prior to study inclusion varied from 3 to 7  years across 
groups. The lowest duration was among patients in SU 
add-on therapy (3.0 years) and the highest in GLP-1 RAs 
(6.5 years) and SGLT-2 inhibitors (7.2 years). A majority 
of patients were men (ranging from 56% among GLP-1 
RA and up to 63% in the insulin group), and mean age 
ranged from 58 to 62 years—GLP-1 RA and DPP-4 inhib-
itor respectively (Table 1). The number of patients at high 
or very high cardiovascular risk according to the EASD/
ESC criteria was greater among those who started add-
on GLP-1 RA or SGLT-2 inhibitor treatment (36% at high 
or very high risk) as compared to insulin (30%), DPP-4 
inhibitors (26%) and SUs (17%). Hypertension was pre-
sent in 35–50% of patients, less frequently among add-
on SU and most frequently in GLP-1 RA. Ischemic heart 
disease was prevalent in 11–16% of patients, lowest in SU 
and SGLT-2 inhibitor groups and highest among those in 
add-on GLP-1 RA. The burden of comorbidities includ-
ing cancer and renal disease was largest in the insulin 
group. The majority of patients were treated with statins, 
ranging from 63% in the SGLT-2 group to 89% in the 
GLP-1 RA group. Use of ACE inhibitors or angiotensin II 
receptor blockers were frequently used and ranged from 
55% to 69% respectively (Table 1).
Hospitalisation for heart failure
During follow-up, a total of 623 (1.3%) patients were hos-
pitalised for HF. Event rates per 1000 patient years were 
5.9 (5.0–6.9) for GLP-1 RA, 4.9 (3.0–7.7) for SGLT-2 
inhibitors, 6.9 (6.0–7.9) for DPP-4 inhibitors, 5.5 (4.4–
6.7) for SU, and 11.7 (9.9–13.7) for insulin (Table  2). 
When compared to patients who started add-on DPP-4 
inhibitors, initiation of GLP-1 RAs; hazard ratio (HR) 
1.11 (95% CI 0.89–1.39), SGLT-2 inhibitors, HR 0.84 
(0.52–1.36), and SU, HR 0.98 (0.77–1.26) was not associ-
ated with any significant differences in risk of hospitalisa-
tion for HF. Insulin was associated with an increased risk 
of hospitalisation for HF, HR 1.54 (1.25–1.91) (Figs. 3 and 
4).
MACE (myocardial infarction, stroke or CV death)
The composite endpoint occurred in 1196 (2.5%) patients 
of which there were 480 myocardial infarctions, 530 
strokes, and 257 CV deaths registered for all patients. 
Event rates per 1000 patient years were 10.1 (8.9–11.4) 
for GLP-1 RAs, 9.3 (6.5–12.9) for SGLT-2 inhibitors, 13.5 
(12.2–15.0) for DPP-4 inhibitors, 13.8 (12.1–15.7) for SU, 
and 19.9 (17.5–22.3) for insulin (Table  2). GLP-1 RAs 
were associated with a lower risk of the composite end-
point, HR 0.82 (0.69–0.97), whereas SGLT-2 inhibitors, 
HR 0.79 (0.56–1.12), SU, HR 1.22 (1.03–1.49) and insulin, 
HR 1.23 (1.07–1.47) were associated with a similar risk as 
compared to DPP-4 inhibitors (Figs. 3 and 4).
All‑cause mortality
A total of 1865 (3.9%) patients died, yielding event rates 
per 1000 patient years of 11.0 (9.7–12.3) for GLP-1 RA, 
11.6 (8.5–15.5) for SGLT-2 inhibitors, 18.3 (16.8–19.9) 
for DPP-4 inhibitors, 19.2 (17.2–21.4) for SU, and 49.3 
(45.6–53.2) for insulin (Table  2). Relative to add-on 
DPP-4 inhibitors, GLP-1 RAs, HR 0.91 (0.78–1.05), 
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SGLT-2 inhibitors, HR 0.79 (0.58–1.07), and SU, HR 
1.13 (0.99–1.31) were not associated with significant 
differences in risk of all-cause mortality. Insulin, HR 
2.33 (2.08–2.61) was associated with an increased risk 
of death (Figs. 3 and 4).
Changes in treatment regimen during follow‑up
At the end of follow up, 82% of patients remained on 
the glucose-lowering treatment they initiated at study 
inclusion; 83% for GLP-1 RAs, 80% for SGLT-2 inhibi-
tors, 76% for DPP-4 inhibitors, 82% for SU, and 91% for 
insulin. Of the patients not initiating insulin therapy, 
8% filled at least one prescription for insulin during fol-
low-up; 12% for GLP-1 RAs, 6% for SGLT-2 inhibitors, 
11% for DPP-4 inhibitors, and 6% for SU.
Sensitivity analyses
The overall associated risk of study outcomes did not 
change considerably for most of the sensitivity analyses 
(Additional file  1: Table  S3–S5). When taking changes 
in treatment throughout follow-up into account, risk 
estimates of all-cause mortality were reduced for GLP-1 
RA, HR 0.71 (0.57–0.89) and SGLT-2 inhibitors, HR 
0.52 0.32–0.87). Conversely, SU was associated with an 
13,148 patients
(GLP-1 receptor 
agonists)
2,343 patients
(SGLT-2 
inhibitors)
15,426 patients in 
(DPP-4 inhibitors)
8,917 patients
(sulfonylurea (SU))
7,152 patients
(insulin) 
84,852 patients started second line 
antidiabetic therapy treatment between 2010-
2016 after prior metformin treatment
29,392 excluded due to discontinuation
of metformin after initiation of second 
line treatment
55,460 patients initiated add-on therapy 
to metformin between 2010-2016
8,153 excluded due to prior 
cardiovascular disease
108 patients excluded due to insufficient 
data registration 
213 died between the initiation of add-on 
therapy and date of inclusion.
46,986 patients with no prior 
cardiovascular events who initiated add-
on therapy were identified
Fig. 2 Consort Diagram for the inclusion and exclusion of patients in the study—GLP-1 glucagon like peptide‑1 analogues, SGLT-2 sodium–glucose 
transporter 2 inhibitor, DPP-4 dipeptidyl peptidase inhibitor. Add‑on therapy is the introduction of a new glucose‑lowering drug in addition to 
on‑going metformin treatment
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increased mortality, HR 1.35 (1.13–1.60), Additional 
file  1: Table  S2. Furthermore, in the sensitivity analysis 
using SU as the reference group as opposed to DPP-4 
inhibitors, DPP-4 inhibitors, GLP-1 RAs and SGLT-2 
inhibitors were associated with a reduced the risk of the 
Table 1 Baseline characteristics according to second-line therapy in addition to metformin
Data is n(%) or mean (SD)
ACE-I Angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, GLP-1 RA glucagon like peptide-1 receptor agonists, SGLT-2 sodium–glucose 
transporter 2 inhibitor, DPP-4 dipeptidyl peptidase inhibitor
a cardiovascular risk was assed according to EASD/ESC guidelines within the limitation of the registries. DPP-4 is used as reference for all comparisons
b Marks values which are significantly different from DPP-4 inhibitors
DPP‑4 inhibitors GLP‑1 receptor agonists SGLT‑2 inhibitors Sulfonylurea Insulin p value
Number of patients 15,426 (33%) 13,148 (28%) 2343 (5%) 8917 (19%) 7152 (15%)
Male 9160 (59%) 7403 (56%)b 1398 (60%) 5473 (61%) 4480 (63%)b
Age 62.4 (± 11.9) 58.0 (± 11.2) 60.2 (± 11.3) 59.6 (± 12.0) 61.2 (± 13.2) < 0.0001
Years in metformin monotherapy 5.1 (± 4.0)  6.5 (± 4.5)  7.2 (± 5.1) 3.0 (± 3.0) 4.7 (± 4.4) < 0.0001
Follow‑up (years) 1.8 (± 0.4) 1.9 (± 0.3) 1.4 (± 0.6) 1.8 (± 0.4) 1.7 (± 0.5) < 0.0001
Cardiovascular  riska
 Moderate 11,370 (74%) 8423 (64%)b 1489 (64%)b 7401 (83%)b 5007 (70%)b
 High 1461 (9%) 2157 (16%)b 563 (24%)b 233 (3%)b 758 (11%)
 Very high 2595 (17%) 2568 (20%)b 291 (12%)b 1283 (14%)b 1387 (19%)b
Medical history
 Chronic obstructive pulmonary disease 945 (6%) 920 (7%) 113 (5%) 568 (6%) 652 (9%)b
 Hypertension 6145 (40%) 6523 (50%)b 841 (36%)b 3162 (35%)b 3160 (44%)b
 Atrial fibrillation 1409 (9%) 1106 (8%) 121(5%)b 757 (8%) 741 (10%)
 Cancer 2125 (14%) 1630 (12%)b 232 (10%)b 1133 (13%) 1373 (19%)b
 Thyroid disease 356 (2%) 386 (3%) 57 (2%) 183 (2%) 194 (3%)
 Renal disease 1245 (8%) 1390 (11%)b 109 (5%)b 477 (5%)b 772 (11%)b
 Ischemic heart disease 1993 (13%) 2089 (16%)b 249 (11%)b 1013 (11%)b 1008 (14%)
 Peripheral arterial disease 378 (2%) 384 (3%) 37 (2%) 175 (2%) 290 (4%)
Pharmacotherapy
 Statin 10,902 (71%) 11,758 (89%)b 1477 (63%)b 6139 (69%) 4648 (65%)b
 ACE‑I/ARB 9630 (62%) 9120 (69%)b 1277 (55%)b 5458 (61%) 4284 (60%)b
 Spironolactone 933 (6%) 1201 (9%)b 90 (4%)b 546 (6%) 628 (9%)b
 Thiazide 3096 (20%) 3173 (24%)b 304 (13%)b 1797 (20%) 1484 (21%)
 Calcium channel blockers 5354 (35%) 5389 (41%)b 622 (27%)b 2973 (33%) 2460 (34%)
 Beta blockers 4276 (28%) 4076 (31%)b 503 (21%)b 2332 (26%) 1961 (27%)
 Clopidogrel 1048 (7%) 988 (8%) 101 (4%)b 521 (6%) 531 (7%)
 Digoxin 567 (4%) 370 (3%)b 30 (1%)b 317 (4%) 335 (5%)
 Acetylsalicylic acid 5472 (35%) 5942 (45%)b 645 (28%)b 2844 (32%) 2623 (37%)b
 Furosemide 2739 (18%) 3162 (24%)b 259 (11%)b 1458 (16%) 1728 (24%)b
Table 2 Event rates of hospitalisation for HF, MACE and all-cause mortality according to second-line therapy
Heart failure hospitalisation MACE All‑cause mortality
No events Rate per 1000 py No events Rate per 1000 py No events Rate per 1000 py
DPP‑4 inhibitors 203 6.9 (6.0–7.9) 398 13.5 (12.2–15.0) 542 18.3 (16.8–19.9)
GLP‑1 receptor agonists 151 5.9 (5.0–6.9) 261 10.1 (8.9–11.4) 285 11.0 (9.7–12.3)
SGLT‑2 inhibitors 19 4.9 (3.0–7.7) 36 9.3 (6.5–12.9) 45 11.6 (8.5–15.5)
Sulfonylurea 94 5.5 (4.4–6.7) 236 13.8 (12.1–15.7) 330 19.2 (17.2–21.4)
Insulin 156 11.7 (9.9–13.7) 265 19.9 (17.5–22.3) 663 49.3 (45.6–53.2)
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Fig. 3 Crude cumulative incidence plot for the events of hospitalisation for heart failure, composite MACE endpoint (myocardial infarction, stroke, 
or cardiovascular death), and all‑cause mortality. GLP-1 glucagon like peptide‑1 receptor agonist, SGLT Sodium–glucose transporter 2 inhibitor, 
DPP-4 dipeptidyl peptidase 4 inhibitor
Page 8 of 11Thein et al. Cardiovasc Diabetol          (2020) 19:107 
MACE outcome and all-cause mortality (only DPP-4 and 
SGLT-2 inhibitors). Additional file 1: Table S6).
Discussion
In this nationwide registry-based cohort study, we exam-
ined whether the benefits of GLP-1 RAs and SGLT-2 
inhibitors could be extrapolated to patients with T2D at 
a lower CV risk without prior cardiovascular events who 
initiated second-line glucose lowering therapy to met-
formin. We found a low absolute risk of hospitalisation 
for HF amongst differing second-line treatments, and no 
significant differences in risk compared to patients who 
started add-on DPP-4 inhibitors, with the exception of 
an increased risk with add-on insulin therapy. For the 
MACE endpoint we found that add-on GLP-1 RA ther-
apy was associated with a ~ 30% lower risk. SU and insu-
lin were associated with a higher risk of MACE. SGLT-2 
inhibitors was not associated with a significantly different 
risk compared to the DPP-4 inhibitor group, but a poten-
tial signal towards a benefit of add-on SGLT-2 inhibitors 
may be argued for, as the number of cases and patients 
in the SGLT-2 inhibitor group were relatively low. A 
relatively high proportion of the cohort received GLP-1 
RAs as compared to SGLT-2 inhibitors. While specula-
tive, we believe this may be due to the weight-loss effects 
of the GLP-1 RA as well as the time frame in which the 
CV outcome trials were presented, and the guidelines 
were updated. When comparing GLP-1 RAs and SGLT-2 
inhibitors to DPP-4 inhibitors, our findings suggest that 
the benefits of GLP-1 RAs and SGLT-2 inhibitors dem-
onstrated in clinical trials—for patients with T2D and 
established CV disease, or a high cardiovascular risk pro-
file—may be somewhat lessened in a nationwide popula-
tion of T2D patients at moderate CV risk. For all-cause 
mortality, insulin use was associated with a higher risk of 
death while no differences were observed for GLP-1 RAs, 
SGLT-2 inhibitors and SUs relative to DPP-4 inhibitors.
The cardiovascular safety of GLP-1 RAs, SGLT-2 
inhibitors, and DPP-4 inhibitors has been investigated in 
RCTs that primarily included patients with established 
Fig. 4 Forrest plot of risk of adverse outcomes according to add‑on therapy. Hospitalisation for heart failure, composite MACE endpoint of MI, 
stroke, or cardiovascular (CV) death, and all‑cause mortality according to second‑line add‑on treatment. GLP-1 RA glucagon like peptide‑1 receptor 
agonist, SGLT-2 sodium–glucose cotransporter 2 inhibitor, DPP-4 dipeptidyl peptidase inhibitor. The results visualised in the Forest plot is adjusted for 
age, comorbidities time in metformin monotherapy, year of inclusion, use of statin, CV risk profile, and sex. DPP‑4 inhibitors were used as reference
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cardiovascular disease or with multiple risk factors [17, 
22, 24, 32–34]. The mechanisms explaining the cardio-
vascular benefits of GLP-1 RAs and SGLT-2 inhibitors 
are not clear, but they do not seem to be mediated by a 
reduction in HbA1c [35, 36]. Some studies have suggested 
that the effects may be driven by individual drugs rather 
than the class of drugs—both in terms of varying effects 
demonstrated in clinical trials as well as observational 
studies [32, 37]. Meta-analyses on SGLT-2 inhibitors, 
GLP-1 RAs, and DPP-4 inhibitors have not, however, 
demonstrated significant treatment effect heterogene-
ity within each drug class [38, 39]. Other observational 
studies on patients with T2D have for hospitalisation for 
HF found a similar risk for GLP-1 RAs, a decreased risk 
for SGLT-2 inhibitors, and an increased risk for DPP-4 
inhibitors when compared to a reference group [16, 
40–44]. The difference between these results and those 
found in this study may be a product of the variance in 
study design, as these studies tend to compare one drug 
or class of drugs to all other treatment modalities. This 
simplification may allow specific treatments in the refer-
ence group (e.g. insulin) to drive the results. Direct com-
parisons of SGLT-2 inhibitors and DPP-4 inhibitors have 
been done in propensity matched analyses by using both 
Scandinavian and American registries and found SGLT-2 
inhibitors to be associated with a reduction in the risk of 
hospitalisation for HF [25, 42]. The discrepancy between 
the findings of these and the present study—which did 
not find SGLT-2 inhibitors to be associated with lower 
risk of hospitalisation for HF—may be explained by the 
difference in study design. The aforementioned studies 
included patient with established cardiovascular disease 
(30%), and on-going metformin treatment in 60–80% of 
patients [25, 42]. Additionally, our findings show that the 
use of SU and insulin were associated with an increased 
risk of MACE and for insulin all-cause mortality as well. 
A recent clinical trial has demonstrated cardiovascular 
non-inferiority when comparing Linagliptin (a DPP-4 
inhibitor) with Glimepiride (an SU) [45, 46].
In the sensitivity analysis taking changes to the ini-
tial add-on therapy during follow-up into account, 
GLP-1 RAs and SGLT-2 inhibitors were associated with 
a reduced risk of all-cause mortality. The discrepancy 
between the primary analysis and the sensitivity analy-
sis may reflect that changes to the add-on therapy are 
made when the underlying disease progresses, rather 
than displaying the direct beneficial results of the treat-
ment. When we excluded patients deemed at high or very 
high risk, the association between add-on GLP-1 RAs or 
SGLT-2 inhibitor and CV outcomes were somewhat less-
ened for hospitalisation for HF and the composite MACE 
outcome. These analyses may help to explain why our 
results do not fully mirror the benefits found for SGLT-2 
inhibitors and GLP-1 RAs in recent CV outcome trials in 
patients with established or at high risk of CV disease.
Limitations
The present study was observational, and the associa-
tions observed may not represent causality. The choice 
of second-line add-on therapy may be influenced by a 
multitude of factors that cannot fully be captured in the 
adjusted analyses. The lack of information on important 
clinical variables including blood glucose and kidney 
function raises the risk of confounding by indication. 
Other clinical variables, including BMI, smoking status, 
and blood pressure were not available. However, surro-
gate measures for some of these parameters were estab-
lished and adjusted for based on hospital admissions, 
e.g. for kidney disease and hypertension. Additionally, 
the continuous use of metformin indicated that the kid-
ney function was not severely reduced. As comorbidi-
ties associated with cardiovascular risk were assessed by 
ICD-10 coding during hospital admission or outpatient 
visits, patients with stable vascular disease may have 
been included and characterised as being at moderate 
cardiovascular risk. Further, the study may be limited by 
the follow-up period of 2 years in patients at lower risk. 
The results of the SGLT-2 inhibitors may be limited by 
the relatively low number of patients and events in the 
SGLT-2 inhibitor group. Lastly, We chose not to include 
glitazones and alpha-glucosidase inhibitors as use of 
these drugs was low.
Conclusions
In a nationwide cohort of patients with T2D starting 
second-line add-on therapy with metformin and with 
no history of cardiovascular events, initiating either 
GLP-1 RA or SGLT-2 inhibitor treatment was associ-
ated with comparable risks of hospitalisation for HF 
and death, and a lower risk of the composite endpoint 
of MI, stroke, or CV death for GLP-1 RAs, relative to 
DPP-4 inhibitors. Our results suggest that the benefits 
of these drugs found in CV outcome trials might not be 
readily extrapolated to patients with T2D at moderate 
risk of cardiovascular disease. Prospective and prag-
matic head-to-head trials comparing cardiovascular 
risk associated with different glucose-lowering thera-
pies in primary prevention populations are warranted.
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